Tumor lysis syndrome induced by tebentafusp

Article Oncology

Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study

Dirk Tomsitz et al.

Summary: A retrospective, multicenter study was conducted to analyze the outcomes and safety of tebentafusp therapy in 78 patients with metastatic uveal melanoma (mUM). The study showed that patients treated with tebentafusp had a median progression-free survival (PFS) of 3 months and a median overall survival (OS) of 22 months. There was a higher rate of patients with elevated LDH in this cohort compared to a published Phase 3 study. Patients treated with tebentafusp following immune checkpoint inhibitor (ICI) therapy had a trend for a longer OS.

CANCERS (2023)

添加到收藏夹

Article Oncology

Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)

F. Stephen Hodi et al.

Summary: The CheckMate 218 study investigated the safety and efficacy of nivolumab plus ipilimumab in patients with advanced melanoma, reporting high survival rates and consistent safety outcomes across multiple patient subgroups. The combination therapy demonstrated promising results and further supports its use in the treatment of advanced melanoma.

MELANOMA RESEARCH (2021)

添加到收藏夹

Article Medicine, General & Internal

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Paul Nathan et al.

Summary: The randomized trial of tebentafusp for metastatic uveal melanoma showed a higher 1-year overall survival rate among patients who received tebentafusp compared to those who received the investigator's choice of therapy, indicating superior efficacy.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology